Sophie Postel-Vinay

19PUBLICATIONS
179CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesGene and molecular therapyMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jun 01, 2026
Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.

|Mar 31, 2026
Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.

Juanita S Lopez, Kevin J Harrington, Seock-Ah Im

|Jul 29, 2025
Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers.

Roman M Chabanon, Liudmila Shcherbakova, Magali Lacroix-Triki

|Apr 24, 2025
Barriers to publishing early phase clinical trials: the oncologists' perspective.

Merel J J Lucassen, Pedro Bergmann, Olga Husson

|Apr 23, 2025
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Noé Herbel, Sophie Postel-Vinay

|Feb 12, 2025
AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors.

Lillian L Siu, Sophie Postel-Vinay, Rafael Villanueva-Vázquez

Pageof 4

Frequent Collaborators

5 joint publications

Roman M Chabanon

4 joint publications

Christopher J Lord

3 joint publications

Antoine Italiano

3 joint publications

Christophe Massard